IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$3.75
−6.84%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -14.3%
- EBIT
- —
- EPS
- +42.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -38.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- +12.6%
- EBIT
- +7.3%
- Net income
- +8.2%
- EPS
- +37.7%
- Free cash flow
- +17.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026